An unexpected case of atypical femur fracture misdiagnosed as radiculopathy and hip osteoarthritis: A patient treated with bisphosphonate Bisfosfonat tedavisi alan bir hastada radikulopati ve kalça osteoartritini taklit eden atipik femur kiriği: Olgu sunumu

Saral İ., Durmuș O., AĞIRMAN M., ÖRMECİ T., Çakar E.

Turk Geriatri Dergisi, vol.18, no.2, pp.176-178, 2015 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 2
  • Publication Date: 2015
  • Journal Name: Turk Geriatri Dergisi
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.176-178
  • Keywords: Alendronate, Bisphosphonates, Femoral fractures
  • Istanbul Medipol University Affiliated: Yes


Bisphosphonates are the most commonly used drugs in the treatment of osteoporosis. Several randomized controlled studies have proved their effectiveness in the treatment of postmenopausal osteoporosis and today BPs are considered a first-line therapy for osteoporosis. Bisphosphonates inhibit osteoclastic activity, decrease bone turnover and increase bone mineral density. Although there is strong evidence that bisphosphonates prevent osteoporotic fractures, in recent years, there have been several reports that show the increasing risk of atypical femoral fractures that is related to prolonged usage (5 years or longer) of bisphosphonates. This may be related to prolonged suppression of bone turnover. By suppressing the bone turnover they impair the ability of bone to repair the microdamages and leads the accumulation of microcracs. In this case, we report 67-year-old female who presented with atypical femoral fracture.